Evaluation of the effect of melatonin in reducing migraine attacks in comparison with standard treatment in patients treated in Shahid Sadoughi Hospital in Yazd

Evaluation of the effect of melatonin in reducing migraine attacks in comparison with standard treatment in patients treated in Shahid Sadoughi Hospital in Yazd, a double-blind randomized clinical trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240220061059N2

Enrollment

Registered

2024-08-12

Start date

2024-07-22

Completion date

Unknown

Last updated

2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

migraine headache. Migraine

Interventions

Intervention 1: Intervention group: Taking 5 mg melatonin tablets (Razak company) daily for three months. Intervention 2: Control group: Receiving a placebo in the form of melatonin tablets 5 mg daily

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: age over 18 years all patients with migraine who referred to the neurology clinic of Shahid Sadoughi Hospital in Yazd

Exclusion criteria

Exclusion criteria: Lack of consent to enter the study pregnancy lactation

Design outcomes

Primary

Measure	Time frame
Migraine headache severity using two standard criteria. Timepoint: baseline and 12 weeks later. Method of measurement: Global assessment of migraine severity (GAMS) ? MEGSEV Criteria.	—

Secondary

Measure	Time frame
The number of days the patient had a migraine attack in the last month. Timepoint: At the end of the first, second and third month. Method of measurement: Through the researcher's face-to-face meeting with the patient in the clinic or through the researcher's phone call with the patient, the researcher obtains information about the number of days the patient had migraine attacks in the last month and writes it down in the questionnaire.	—

Measure

Time frame

The number of days the patient had a migraine attack in the last month. Timepoint: At the end of the first, second and third month. Method of measurement: Through the researcher's face-to-face meeting with the patient in the clinic or through the researcher's phone call with the patient, the researcher obtains information about the number of days the patient had migraine attacks in the last month and writes it down in the questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGolnaz Afzal

Yazd University of Medical Sciences

dr.golnaz.afzal@gmail.com+98 35 3820 3865

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026